Israel - English - Ministry of Health

megapharm ltd - palifermin 6.25 mg/vial - solution for injection - palifermin - kepivance is indicated to decrease the incidence, duration and severity of oral mucositis in patients with haematological malignancies receiving myeloablative therapy associated with a high incidence of severe mucositis and requiring autologous haemopoietic stem cell support.

European Union - English - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - palifermin - mucositis - all other therapeutic products - kepivance is indicated to decrease the incidence, duration and severity of oral mucositis in adult patients with haematological malignancies receiving myeloablative radiochemotherapy associated with a high incidence of severe mucositis and requiring autologous-haematopoietic-stem-cell support.

Canada - English - Health Canada

swedish orphan biovitrum ab (publ) - palifermin - powder for solution - 6.25mg - palifermin 6.25mg - cell stimulants and proliferants

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - palifermin - powder for solution for injection - 6.25mg